Can Targeting Replication Fork Stalling Be a Therapeutic Strategy?
Yes, targeting replication fork stalling is a promising therapeutic strategy in cancer treatment. Agents that induce replication stress, such as topoisomerase inhibitors and DNA crosslinking agents, are already used in chemotherapy. Additionally, inhibitors of key proteins involved in fork stabilization and repair, like PARP inhibitors, exploit the vulnerabilities of cancer cells with defective fork repair mechanisms.
